Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy

Sep.14
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.

Key Points

  • Shenzhen Smoore Technology and distributors Jupiter Research, Greenlane Holdings, 3Win and Canna Brand Solutions are seeking dismissal of the direct purchasers' per se horizontal conspiracy claim.
  • Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on discounting among authorized distributors; the allegations have not been established by the court.
  • Smoore argues that the arrangements were vertical distribution practices between a manufacturer and individual distributors, not an automatically unlawful agreement among competitors.
  • The litigation forms part of a broader CCELL antitrust MDL; the current motion targets a core claim in the direct-purchaser case rather than seeking dismissal of the entire MDL.

2Firsts

September 14, 2026

According to Law360 on September 10, 2026, Shenzhen Smoore Technology Co., Ltd. and four authorized U.S. distributors of CCELL products have asked a California federal court to permanently dismiss a core antitrust class claim brought by direct purchasers, arguing that the alleged pricing and customer arrangements reflect vertical dealings between a manufacturer and distributors rather than a horizontal price-fixing conspiracy.

The motion was filed on September 4 in the U.S. District Court for the Northern District of California.

The litigation is part of In re: CCell Closed Cannabis Oil Vaporization Systems and Components Products Antitrust Litigation, case No. 3:25-md-03161, before U.S. District Judge Vince Chhabria.

Plaintiffs Allege Minimum Pricing and Customer Allocation

The current dispute involves a second amended consolidated class action complaint brought by direct purchasers Meridian Partners II LLC and Redbud Roots Inc.

Along with Smoore, the defendants include four authorized CCELL distributors: Jupiter Research LLC, Greenlane Holdings Inc., 3Win Corp. and CB Solutions LLC, which does business as Canna Brand Solutions.

The plaintiffs allege that Smoore used its position in the cannabis vaping hardware market to organize and enforce pricing and customer arrangements among its authorized distributors.

According to the complaint, distributors agreed to minimum wholesale prices, refrained from competing for certain customers and avoided undercutting one another on price. Plaintiffs also allege that Smoore required authorized distributors to sell only CCELL products and barred them from carrying rival vaping products.

The plaintiffs seek to characterize the arrangements as a horizontal agreement among competitors subject to the Sherman Act's per se rule, under which certain forms of price-fixing and customer allocation can be treated as unlawful without a broader inquiry into market effects.

Those allegations have not been established by the court.

Smoore Says Conduct Was Vertical Distribution Management

Smoore and the four distributors dispute that characterization.

In their dismissal motion, the defendants argue that the second amended complaint still describes separate business relationships between Smoore and individual distributors rather than an agreement among the distributors themselves.

They characterize the alleged arrangements as textbook vertical conduct and say the documents cited by the plaintiffs show how Smoore operated its distribution system, not that competing distributors reached a horizontal agreement.

The distinction matters to the antitrust analysis.

Price-fixing or customer-allocation agreements among competitors can fall within the per se rule, while restrictions imposed in vertical manufacturer-distributor relationships generally require a broader assessment of their competitive effects.

The central dispute is therefore whether CCELL's U.S. distribution structure amounted to vertical channel management or whether Smoore coordinated a horizontal agreement among distributors.

2018 Meeting Again Cited by Plaintiffs

The latest complaint also relies on allegations concerning a 2018 meeting involving the defendants as evidence of coordination among distributors.

Smoore and the distributors argue that the meeting allegations had previously been presented to the court and still do not establish a horizontal agreement.

The defendants are also asking the court not to give the plaintiffs another opportunity to amend the claim.

The court previously dismissed a similar per se horizontal conspiracy claim brought by the direct purchasers. That ruling did not terminate the broader CCELL multidistrict litigation.

Proposed Class Reaches Back to at Least 2016

The proposed direct-purchaser class seeks to represent buyers of unfilled CCELL vaporization systems and components in the United States and its territories from at least December 1, 2016, through the period in which the alleged effects of the purported conspiracy continued.

The plaintiffs seek nationwide relief, including treble damages, attorneys' fees and injunctive relief.

The larger MDL also includes similar claims brought by consumers and other indirect purchasers.

The cases were centralized in the Northern District of California for coordinated proceedings and involve allegations concerning CCELL pricing, distribution restrictions, competing products and relationships among market participants.

The September 4 motion therefore does not seek dismissal of the entire MDL. It targets the direct purchasers' renewed per se horizontal conspiracy theory.

CCELL Distribution Practices Face Antitrust Test

CCELL is one of Smoore's major hardware brands serving cannabis-oil vaporization applications.

The litigation places several common channel-management practices under U.S. antitrust scrutiny, including minimum pricing, customer boundaries among authorized distributors and restrictions involving competing products.

The plaintiffs contend that those practices went beyond separate manufacturer-distributor relationships and became a Smoore-coordinated horizontal arrangement among distributors. Smoore is asking the court to treat the conduct as vertical distribution management and dismiss the per se claim.

The court's handling of the second amended complaint and the latest dismissal motion will determine whether the direct purchasers can continue pursuing this part of the case under a horizontal price-fixing and customer-allocation theory.

Follow 2Firsts for timely updates on global tobacco and nicotine industry developments, corporate strategy and market trends.

Cover Image: ccell

U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
The U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives said on September 23 that it has joined the interagency Trade Fraud Task Force to strengthen enforcement against illegal, misdeclared and smuggled vape and tobacco products. ATF will bring its authority under the Prevent All Cigarette Trafficking Act into the task force, including registration, reporting, shipping and record-inspection requirements covering interstate sales of electronic nicotine delivery systems. ATF said the move will strengthen its ability to trace illicit products from U.S. points of entry through domestic trafficking and distribution networks.
News
Sep.28 by 2Firsts Perspectives
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
South Korea Fully Reviews Nicotine-Analog and Nicotine-Free Vape Liquid Imports, With Over 99% From China and Chinese Supply-Chain Documents Under Scrutiny
Korea Customs Service has tightened import controls on nicotine-analog and nicotine-free e-cigarette liquids, placing the products under 100% document review and subjecting all e-cigarette liquid import declarations to pre-clearance ingredient analysis. As of September 20, 2026, South Korea had imported about 15 metric tons of nicotine-analog liquids, 99.99% from China, and about 316 metric tons of nicotine-free liquids, including roughly 315 metric tons, or 99.7%, from China. The measures follow South Korea's April expansion of its tobacco definition to include synthetic nicotine products and include new checks on Chinese manufacturing, transaction and export documentation.
Sep.24
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08